Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

huCART19-IL18

Phase 1Biologic

UUniversity of Pennsylvania

huCART19-IL18 is one of 10 biologic programs targeting Cancers. It is currently in Phase 1.

1

Indications

1

Total Trials

1

Active Trials

9

Competitors

Pipeline

Status by Indication[3][1]

Indication

CancersActive, not recruiting

CancersPhase 1

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Cancers

#DrugCompanyPhaseTrials

Keytruda

Gemzar

Johnson & Johnson

Tafinlar

Gleevec

Mekinist

Jemperli

GGlaxo Dba Glaxosmithkline

Telisotuzumab Adizutecan

Hyperpolarized 13c Pyruvate

UUniversity of Maryland, Baltimore

Upifitamab Rilsodotin

MMersana Therapeutics

huCART19-IL18

UUniversity of Pennsylvania

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2036

Phase 1Active, not recruiting

Cancers

NCT04684563

Clinical

Trials by Indication[1]

Cancers1 trial

huCART19-IL18 in CD19+ Cancers

Active, not recruiting·UUniversity of Pennsylvania·Phase 1·NCT04684563·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for huCART19-IL18. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — huCART19-IL18 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for huCART19-IL18. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Pennsylvania company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Pennsylvania

Related News